Sign InSummary
Novavax, Inc. saw a 7.62% rise in its stock price due to significant events in the healthcare sector and rising COVID-19 infection cases in the United States, but the company is still far from its year high and its negative earnings reduce its attractiveness for investors, although there is potential for growth according to Wall Street consensus and discounted cash flow price analysis; caution is advised due to approaching overbought scenario and high volatility.
Fundamental Analysis
Novavax, Inc. (NVAX) is a biotechnology company that focuses on developing vaccines, and saw a closing price of $9.74 as of September 06, 2023. Recent reports pointed out performance highlights for the stock, such as a noticeable 7.62% rise, resulting from significant events in the healthcare sector and rising COVID-19 infection cases in the United States.
Despite the recent rise, NVAX is still far from its year high of $33.37. Comparatively, the current price sits closely above its year low of $5.61. A significant downside is the negative EPS of -$7.33, and a negative P/E ratio of -1.33. These numbers indicate the company currently isn't profitable, reducing its attraction for dividend or earnings-focused investors.
The market capitalization of Novavax stands at $982.80 million, making it a small-cap stock. With the average volume of 7.62 million shares, the trading volume on the last trading day was relatively high, with 27.98 million shares changing hands. This is indicative of higher investor interest in the stock.
Despite a series of news pointing towards a potential drop in biotech stocks, NVAX has received a 'Buy' consensus from Wall Street, with 8 'buy' recommendations and 5 'hold' ones. Moreover, the discounted cash flow (DCF) price of $26.84 is healthier than the current price.
The company is expected to announce its earnings on November 6, 2023, which could serve as an essential catalyst for the stock's near-term price movement.
Technical Analysis
From a technical perspective, Novavax's current price level is just above the 50 days moving average of $8.02, suggesting a bullish trend in the short term. Further, the RSI14 stands at 71, indicating the stock is on the verge of being overbought. However, the MACD 3-month is 0.078155, showing a positive trend.
Furthermore, the ATR figure (average true range) of NVAX is 7.64, which indicates volatility. Despite the high volatility, investors seem comfortable as Novavax's current price surpasses its stop-loss price of $9.27 and is also above the support level at $9.36, which should provide some degree of price stability.
Prediction and Recommendation
Taking into account the fundamental and technical factors, the following predictions can be made for NVAX:
- Next Trading Day: Given the recent bullish sentiments and volatility, NVAX's price may rise, though caution is advised due to the approaching overbought scenario. - Upcoming Week: The stock may continue its uptrend buoyed by strong buyer interests. However, it might face resistance around the $10.30 price level. If the stock surpasses this level, further upward movement is possible.
In conclusion, based on the available data and recent market sentiments, NVAX is categorized as a 'Hold' currently. The potential for growth is present, as reflected by its DCF and Wall Street consensus. However, the negative earnings, high volatility and approaching overbought circumstance also bring concerns. Thus, investors are advised to monitor the stock closely, especially around its earnings announcement, and possibly reconsider their position based on the upcoming financial report.
